Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome

Eur Heart J. 2017 May 1;38(17):1285-1293. doi: 10.1093/eurheartj/ehw456.

Abstract

Atrial fibrillation (AF) is a common arrhythmia in patients with aortic stenosis. When these patients are treated medically or by surgical aortic valve replacement, AF is associated with increased risk of adverse events including death. Growing evidence suggests a significant impact of AF on outcomes also in patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). Conversely, limited evidence is available regarding the optimal management of this condition. This review aims to summarize prevalence, pathophysiology, prognosis, and treatment of AF in patients undergoing TAVI.

Keywords: Aortic stenosis; Atrial fibrillation; TAVI.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Aortic Valve Stenosis / complications
  • Aortic Valve Stenosis / mortality
  • Aortic Valve Stenosis / surgery*
  • Atrial Fibrillation / etiology*
  • Atrial Fibrillation / mortality
  • Atrial Fibrillation / therapy
  • Blood Loss, Surgical / statistics & numerical data
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Forecasting
  • Humans
  • Male
  • Postoperative Hemorrhage / etiology
  • Postoperative Hemorrhage / mortality
  • Randomized Controlled Trials as Topic
  • Stroke / etiology
  • Transcatheter Aortic Valve Replacement*
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents